References
- Alberts DS, Mason L (1989). Carboplatin in the treatment of ovarian cancer. Seminars Oncol, 16, 19-26.
- Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships, the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55. https://doi.org/10.1016/0065-2571(84)90007-4
-
Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of
$Loubo^{(R)}$ (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413 - Engel JB, Martens T, Hahne JC, et al (2012). Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anti-Cancer Drugs, 23, 426-36. https://doi.org/10.1097/CAD.0b013e32834fb8ce
- Gietema JA, Guchelaar HJ, de Vries EG, et al (1993). A phase I study of lobaplatin (D-19466) administered by 72h continuous infusion. Anticancer Drugs, 4, 51-5. https://doi.org/10.1097/00001813-199302000-00007
- Gietema JA, De Vries EG, Sleijfer DT, et al (1993). A phase I study of 1, 2-diamminomethyl-cyclobutane-platinum (II)- lactate (D-19466; lobaplatin) admini-stered daily for 5 days. Br J Cancer, 67, 396-401. https://doi.org/10.1038/bjc.1993.73
- Gietema JA, Veldhuis GJ, Guchelaar HJ, et al (1995). Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer, 71, 1302-7. https://doi.org/10.1038/bjc.1995.252
- Harstrick A, Bokemeyer C, Scharnofkse M, et al (1993). Preclinical activity of a new platinum analogue, lobaplatin, in cisplatinsensitive and-resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol, 33, 43-7. https://doi.org/10.1007/BF00686021
- Harstrick A, Casper J, Guba R, et al (1989). Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vitro and in vitro. Cancer, 63, 1079-83. https://doi.org/10.1002/1097-0142(19890315)63:6<1079::AID-CNCR2820630607>3.0.CO;2-J
- Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
- Jakupec MA, Galanski M, Keppler BK (2003). Tumourinhibiting platinum complexes state of the art and future perspectives. Rev Physiol Biochem Pharmacol, 146, 1-54. https://doi.org/10.1007/s10254-002-0001-x
- Kim YH, Kim SC (2011). Recent advances in the biomarkers for epithelial ovarian cancer. J Gynecol Oncol, 22, 219-21. https://doi.org/10.3802/jgo.2011.22.4.219
- McKeage MJ (2001). Lobaplatin, a new antitumour platinum drug. Expert Opin Investig Drugs, 10, 119-28. https://doi.org/10.1517/13543784.10.1.119
- Oguri S, Sakakibara T, Mase H, et al (1988). Clinical pharmacokinetics of carboplatin. J Clin Pharmacol, 28, 208-15. https://doi.org/10.1002/j.1552-4604.1988.tb03134.x
- Ozols RF, Bundy BN, Greer BE, et al (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer, a Gynecologic Oncology Group study. J Clin Oncol, 21, 3194-200. https://doi.org/10.1200/JCO.2003.02.153
- Paine-Murrieta GD, Taylor CW, Curtis RA, et al (1997). Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol, 40, 209-14. https://doi.org/10.1007/s002800050648
- Peng S, Yang QX, Zhang T, et al (2014). Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 5155-60. https://doi.org/10.7314/APJCP.2014.15.13.5155
- Skehan P, Storeng R, Scudiero D, et al (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 82, 1107-12. https://doi.org/10.1093/jnci/82.13.1107
- Suh DH, Kim K, Kim JW (2012). Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol, 23, 53-64. https://doi.org/10.3802/jgo.2012.23.1.53
- Wang N, Lv YZ, Xu AH, et al (2014). Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma. Asian Pac J Cancer Prev, 15, 647-50. https://doi.org/10.7314/APJCP.2014.15.2.647
- Wu XY, Huang XE, Cao J, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4. https://doi.org/10.7314/APJCP.2014.15.14.5941
- Xie C-Y, Xu Y-Pg, Jin W, Lou L-G (2012). Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Anti-Cancer Drugs, 23, 698-705 https://doi.org/10.1097/CAD.0b013e328352cc10
- Voegeli R, SchumacherW, Engel J, et al (1990). D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol, 116, 439-42. https://doi.org/10.1007/BF01612990
- Zhao C, Wang XJ, Wang S, et al (2014). Lobaplatin combined floxuridine/pirarubicin-based transcatheter hepatic arterial chemoembolization for unresectable primary hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 2057-60. https://doi.org/10.7314/APJCP.2014.15.5.2057
Cited by
- Simultaneous quantitation of two diastereoisomers of lobaplatin in rat plasma by supercritical fluid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study vol.38, pp.21, 2015, https://doi.org/10.1002/jssc.201500658
- An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma vol.27, pp.7, 2016, https://doi.org/10.1097/CAD.0000000000000370
- Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma vol.11, pp.5, 2016, https://doi.org/10.3892/ol.2016.4345